Finanzen von NervGen Pharma Corp (NGEN)NGENNervGen Pharma Corp

Evaluating the bottom line, NervGen Pharma Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -757.48%, provide a clear picture of how effectively NGEN converts its operational activities into shareholder value.

In the context of the broader market, NGEN competes directly with industry leaders such as AKBA and ADAG. With a market capitalization of $251.07M, it holds a significant position in the sector. When comparing efficiency, NGEN's gross margin of N/A stands against AKBA's 80.50% and ADAG's 100.00%. Such benchmarking helps identify whether NervGen Pharma Corp is trading at a premium or discount relative to its financial performance.

Nervgen Pharma has shown a significant increase in stock price recently, with a 5-day change of +22.58% and a 20-day change of +40.74%. However, it has reported negative net income consistently, with the latest EPS reported at -0.37, indicating ongoing financial challenges.